Notice of Extraordinary General Meeting in DiaGenic ASA
The board of directors of the Company hereby convenes an extraordinary general meeting.
Time: 22 November 2013 at 10 hours (CET)
Place: Grenseveien 92, Oslo, Norway
Agenda:
- Opening of the meeting by chairman of the board Hanne Skaarberg Holen, including registration of shareholders present
- Election of chairman of the meeting and a person to co-sign the minutes
- Approval of notice and agenda
- Amendment to the articles of association concerning the board of directors
- Election of members to the board of directors and remuneration to the board of directors
- Amendment of the purpose clause in the articles of association
Please see attached Notice for Extraordinary General Meeting for more details on the agenda.
Information regarding the extraordinary general meeting, including this notice with attachments is available at the Company's website www.diagenic.com
On behalf of the Board of directors of DiaGenic ASA
Hanne Skaarberg Holen
Chairman of the Board
Telephone: +47 98 29 45 91
E-mail: hanne.s.holen@adeb.no
About DiaGenic ASA
DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com